Pharmaceuticals

Global Rheumatology Therapeutics Market 2026–2030: Forecast Insights for Business Planning

February 24, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the rheumatology therapeutics market from 2026–2035 with trusted insights from The Business Research Company

By how much is the Rheumatology Therapeutics Market expected to grow between 2026 and 2030?

The rheumatology therapeutics market has shown consistent expansion in recent years. This market is expected to grow from $44.18 billion in 2025 to $46.16 billion in 2026, reflecting a compound annual growth rate (CAGR) of 4.5%. Historically, this growth has been driven by the increasing prevalence of rheumatoid arthritis and osteoarthritis, the broader availability of NSAIDs and corticosteroids, more accurate diagnosis of rheumatic diseases, expanding healthcare access in developed markets, and an increase in the use of conventional synthetic DMARDs.

The rheumatology therapeutics market size is projected to undergo consistent expansion in the coming years, with expectations to reach $54.16 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 4.1%. This anticipated growth during the forecast period is largely attributed to factors such as the increasing demand for biologic DMARDs, a growing elderly population affected by chronic joint disorders, enhanced awareness leading to early diagnosis and treatment, the broader availability of targeted synthetic DMARDs, and increased healthcare expenditure on managing chronic diseases. Furthermore, key trends in this period include the rising adoption of biologic and targeted DMARDs, a strategic shift towards prompt and aggressive disease management, greater utilization of combination therapies for rheumatic conditions, a heightened focus on achieving prolonged disease remission, and the broadening of personalized treatment approaches in rheumatology.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=17246&type=smp

Which Drivers Are Influencing Market Acceleration In The Rheumatology Therapeutics Market?

The increasing incidence of autoimmune conditions is anticipated to fuel expansion in the rheumatology therapeutics market in the coming period. An autoimmune disease refers to a state where the body’s immune system erroneously targets and harms its own tissues. The widespread occurrence of autoimmune disorders is expanding, influenced by a mix of genetic, environmental, and lifestyle elements, alongside heightened awareness and better diagnostic methods. To address autoimmune diseases, rheumatology therapeutics are essential for controlling inflammation, easing symptoms, and preventing harm to joints and tissues resulting from immune system attacks on the body. For example, data from June 2024 provided by the Australian Institute of Health and Welfare, an Australia-based government body, indicated that approximately 514,000 individuals in Australia, representing 2.0% of the population, were estimated to have rheumatoid arthritis in 2022. In 2023, rheumatoid arthritis was responsible for 2.0% of the overall disease burden and 16% of the burden attributed to all musculoskeletal conditions. Consequently, the growing incidence of autoimmune diseases is stimulating the expansion of the rheumatology therapeutics market.

What Leading Segments Are Studied In The Rheumatology Therapeutics Market?

The rheumatology therapeutics market covered in this report is segmented –

1) By Drug Class: Disease Modifying Anti-Rheumatic Drugs, Nonsteroidal Anti-Inflammatory Drugs, Corticosteroids, Uric Acid Drugs, Other Drugs Classes

2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

3) By Disease Indication: Rheumatoid Arthritis, Osteoarthritis, Gout, Psoriatic Arthritis, Ankylosing Spondylitis, Other Disease Indications

Subsegments:

1) By Disease Modifying Anti-Rheumatic Drugs (DMARDs): Conventional Synthetic DMARDs, Biologic DMARDs, Targeted Synthetic DMARDs

2) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): COX-2 Inhibitors, Traditional NSAIDs

3) By Corticosteroids: Oral Corticosteroids, Injectable Corticosteroids, Topical Corticosteroids

4) By Uric Acid Drugs: Uric Acid Lowering Agents, Uricosuric Agents, Pegloticase

5) By Other Drug Classes: Immunosuppressants, Biologic Therapies, Analgesics

How Are New Market Trends Shaping The Landscape Of The Rheumatology Therapeutics Market?

Major companies within the rheumatology therapeutics market are developing innovative solutions, such as intravenous (IV) formulations, aimed at enhancing treatment effectiveness and convenience for patients. An intravenous (IV) formulation refers to a drug or substance administered directly into a vein using a needle or catheter. For instance, in October 2023, Novartis AG, a Switzerland-based pharmaceutical company, announced that the US Food and Drug Administration (FDA) had approved Cosentyx, an intravenous (IV) formulation. This form of Cosentyx has unique approval for the treatment of adults with psoriatic arthritis (PsA), ankylosing spondylitis (AS), and non-radiographic axial spondyloarthritis (nr-axSpA). It functions by specifically targeting and inhibiting interleukin-17A (IL-17A) and stands as the only non-tumor necrosis factor alpha (TNF-a) IV treatment available for these conditions.

Which Key Players Are Driving Competition In The Rheumatology Therapeutics Market?

Major companies operating in the rheumatology therapeutics market are Pfizer Inc., Johnson & Johnson, AbbVie Inc., Roche Holding AG, Merck & Co. Inc., Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Amgen Inc., UCB S.A., Sanofi SA, AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Biogen Inc., Janssen Biotech, Genentech Inc., Galapagos NV

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/rheumatology-therapeutics-global-market-report

Which Region Is Projected To Lead The Rheumatology Therapeutics Market During The Forecast Period?

North America was the largest region in the rheumatology therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rheumatology therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Rheumatology Therapeutics Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=17246&type=smp

Browse Through More Reports Similar to the Global Rheumatology Therapeutics Market 2026, By The Business Research Company

Rheumatology Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/rheumatology-therapeutics-global-market-report

Rheumatoid Arthritis Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/rheumatoid-arthritis-drugs-global-market-report

Rheumatoid Arthritis Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/rheumatoid-arthritis-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795